Skip to main content

Table 1 Characteristics of nanocomposite formulations (Mean ± SD, n = 3)

From: Enhanced oral delivery of insulin via the colon-targeted nanocomposite system of organoclay/glycol chitosan/Eudragit®S100

Formulation Size (nm) PDI Zeta-potential (mV) EE (%)
AC-Ins 192 ± 8.20 0.20 ± 0.01 − 14.0 ± 4.41 97.6 ± 1.20
GAC-Ins 319 ± 9.42 0.46 ± 0.02 15.6 ± 2.31 90.7 ± 3.14
EGAC-Ins 412 ± 10.4 0.32 ± 0.02 − 20.6 ± 0.76 90.3 ± 1.06